Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the safety of adalimumab in patients 2 to < 4
years of age or ≥ 4 years of age weighing < 15 kg, with moderately to severely active
polyarticular juvenile idiopathic arthritis (JIA) or polyarticular course JIA.